Hans Wandall
Co-Founder - Scientific GO Therapeutics
Seminars
Tuesday 4th November 2025
Spotlighting the New Generation of Cancer Specific Glyco-Mucin Targeting ADCs
12:30 pm
- Highlighting ADCs targeting two distinct glyco-MUC1 epitopes and MUC4
- Exploring high target expression in multiple solid tumors
- Demonstrating ADC potent activity in vivo and large therapeutic window
- Evaluating the suite of glyco-Mucin epitopes for novel biparatopic ADC development
Monday 3rd November 2025
Clean Cancer Targets for Better Therapeutics: Going Beyond the Proteome
3:00 pm
- Expanding the ADC target space through clean targeting of all major epithelial cancers through surface exposed glyco-epitopes
- Developing a series of cancer specific antibodies developed as payload- and platform-agnostic glyco-peptide targeting ADCs
- Exploring how GO’s glyco-epitope ADCs provide clean cancer targeting, reduced on-target/off-tumor toxicity, and potent in vivo efficacy and safety
